U.S. Markets close in 4 hrs 49 mins
  • S&P 500

    -10.68 (-0.28%)
  • Dow 30

    -116.76 (-0.38%)
  • Nasdaq

    -26.64 (-0.24%)
  • Russell 2000

    -9.58 (-0.56%)
  • Crude Oil

    +1.78 (+1.68%)
  • Gold

    -5.60 (-0.31%)
  • Silver

    -0.71 (-3.50%)

    -0.0092 (-0.8729%)
  • 10-Yr Bond

    -0.1030 (-3.47%)
  • Vix

    -0.15 (-0.52%)

    -0.0163 (-1.3382%)

    -0.4800 (-0.3536%)

    +258.19 (+1.35%)
  • CMC Crypto 200

    -2.70 (-0.64%)
  • FTSE 100

    -23.14 (-0.32%)
  • Nikkei 225

    -457.42 (-1.73%)

Insiders who purchased Acutus Medical, Inc. (NASDAQ:AFIB) stock last year recover some losses which currently stand at US$78k

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Insiders who purchased US$151k worth of Acutus Medical, Inc. (NASDAQ:AFIB) shares over the past year recouped some of their losses after price gained 11% last week. The purchase, however, has proven to be a pricey bet, with losses currently totalling US$78k.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

Check out our latest analysis for Acutus Medical

Acutus Medical Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when Independent Director James Hinrichs bought US$151k worth of shares at a price of US$3.78 per share. That means that even when the share price was higher than US$1.83 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was James Hinrichs.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!


Acutus Medical is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership of Acutus Medical

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Based on our data, Acutus Medical insiders have about 4.2% of the stock, worth approximately US$2.2m. We consider this fairly low insider ownership.

So What Do The Acutus Medical Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Acutus Medical shares in the last quarter. However, our analysis of transactions over the last year is heartening. The transactions are fine but it'd be more encouraging if Acutus Medical insiders bought more shares in the company. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. You'd be interested to know, that we found 3 warning signs for Acutus Medical and we suggest you have a look.

But note: Acutus Medical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.